It could still be another five years before InDex Pharmaceuticals Holding AB gets approval for its ulcerative colitis (UC) drug cobitolimod but the Swedish biotech has already laid out specific launch plans for the potential blockbuster in the US, where it plans to go to market without a big pharma partner.
The Stockholm-based firm has given an in-depth presentation of the strategy and market potential for cobitolimod, its toll-like receptor 9 (TLR9) agonist, at a capital markets day. A rectal formulation...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?